Anti-angiogenesis drugs that directly target vascular endothelial growth factor (VEGF), a pro-angiogenic protein that increases tumor vasculature and metastatic growth 1,2, are associated with hypertension, proteinuria, and bleeding 2–6. Here, VEGFA is linked to Hypertension.